Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Short communication

Rapid and simultaneous identification of three mutations by the Novaplex™ SARS-CoV-2 variants I assay kit

Wakaki Kami, Takeshi Kinjo, Wakako Arakaki, Hiroya Oki, Daisuke Motooka, Shota Nakamura, Jiro Fujita

A Department of Infectious, Respiratory and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus. 207 Uehara, Nishihara, Okinawa 903-0215, Japan
B Department of Infection Metagenomics, Genome Information Research Center, Research Institute for Microbial Diseases. 3-1 Yamadaoka, Suita, Osaka 565-0871, Japan

ARTICLE INFO

Keywords:
SARS-CoV-2
COVID-19
Variant
Mutations
Whole-genome sequencing

ABSTRACT

Background: The emergence of SARS-CoV-2 variants has caused an unexpected rebound globally. The World Health Organization has listed three variants (B.1.1.7, B.1.351, and P.1) as variants of concern. To understand the epidemiology and thereby plan appropriate safety measures, differential identification of the variants is indeed critical.

Objectives: Although whole-genome sequencing is the gold standard for variant identification, it is time-consuming and relatively expensive. Therefore, a rapid, easy, and cost-effective platform targeting multiple regions of the genome is required. Here, we assessed the usefulness of the Novaplex™ SARS-CoV-2 Variants I Assay kit in identifying mutations in the variants.

Study design: We retrospectively examined 30 stored nasal swabs from COVID-19-positive patients tested between November 2020 and March 2021. RNA extracted from these swabs was subjected to the commercial kit and real-time reverse transcription-PCR was performed. To determine the genome sequences of SARS-CoV-2 in the collected samples and deduce the consensus sequences among the identified variants, genome sequencing libraries were prepared and mapped to the reference genome.

Results: Four of the tested samples were determined as variants. Of them, two harbored both H69/V70 deletion and N501Y substitution, whereas two harbored E484K substitution alone.

Conclusions: The variant with E484K substitution alone ("R.1") has been now categorized as a variant of interest in Japan. Additionally, the kit-based assay was found to be feasible, convenient, and user-friendly in identifying the abovementioned mutations with a turnaround time of only 2 h.

1. Introduction

Although the global advent of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has relieved us from the ongoing pandemic, the emergence of SARS-CoV-2 variants has raised new concerns. The World Health Organization (WHO) defines a SARS-CoV-2 variant of interest (VOI) as a phenotypically changed isolate that causes community transmission or clusters, and a variant of concern (VOC) as a VOI with increased transmissibility and virulence, or decreased effectiveness of public health and social measures or diagnostics, vaccines, and treatment [1]. As of April 13, 2021, WHO has listed three VOCs: B.1.1.7, B.1.351, and P.1, named the UK variant, South Africa variant, and Brazil/Japan variant, respectively, after the places where they were first identified [2]. Among the various mutations emerging in SARS-CoV-2, those in the spike (S) protein, specifically the H69/V70 deletion and E484K N501Y substitution mutations, are important because the S protein is involved in infectivity to host cells via angiotensin-converting enzyme 2 and the main target of neutralizing antibodies induced by vaccines [3]. All three VOCs listed above harbor the N501Y mutation; B.1.1.7 harbors an additional H69/V70 deletion;
2. Materials and methods

We retrospectively examined the stored nasal swabs from COVID-19-positive patients tested at the Ryukyu University Hospital between November 4, 2020 and March 9, 2021. COVID-19 diagnosis was confirmed by real-time PCR with primer sets developed by the National Institute for Infectious Diseases of Japan [7]. RNA was extracted from the nasal swabs stored in a deep freezer using MagLEAD 12 gC (Precision System Science, Chiba, Japan). The extracted RNA was then subjected to genome amplification using ATRIC modified (V3) primer set [8]. Libraries were prepared using the Nextera XT Library Prep Kit (Illumina, San Diego, CA, USA) and random primers pd(N)6 (Takara Bio, Shiga, Japan), whole genome amplification was conducted using ATRIC Network’s modified (V3) primer set [8]. Libraries were prepared using the Nextera XT Library Prep Kit (Illumina, San Diego, CA, USA) with the respective MiSeq v3 Reagent kit. After mapping to the reference genome of SARS-CoV-2 (GenBank accession number: NC_045512.2), consensus sequences were obtained using CLC Genomics Workbench ver. 21.0.2 (QIAGEN, Hilden, Germany). This study was approved by the Institutional Review Board of the University of the Ryukyus (approval number: 1621).

3. Results

A total of 30 COVID-19-positive samples were tested. Among them, four samples collected between February and March were determined to be variants; two (cases 1 and 2) were positive for both H69/V70 deletion and N501Y substitution mutations (UK variant), while the other two (cases 3 and 4) were positive for E484K substitution mutation alone (Table 1). These results were confirmed by whole-genome sequencing (Fig. 1). In terms of usability of the Novaplex™ SARS-CoV-2 Variants I Assay kit, the procedure was simple and easy to perform, and the turnaround time was only 120 min (Fig. 2).

Genome sequence data for the four cases are shown. Reference sequences (Wuhan and Okinawa) and typical mutation patterns are shown in the upper and lower stands, respectively.

PCR mixture was prepared using the extracted RNA and Novaplex™ SARS-CoV-2 Variants I Assay kit reagents; real-time reverse transcription-PCR was performed using the CFX96 Touch Real-Time PCR Detection System. The test results were automatically displayed on the monitor via the software’s interface (Seegene Viewer).

Table 1
Result of PCR performed using the Novaplex™ SARS-CoV-2 Variants I Assay kit.

| Collection Date | RdRP | H69/V70 del | Ct | E484K | Ct | N501Y | Ct |
|-----------------|------|-------------|----|-------|----|-------|----|
| Case 1 February 5 | (+) | 24.23 | (-) | 27.43 | (–) | 0.00 | (+) | 28.08 |
| Case 2 February 19 | (+) | 38.27 | (–) | 37.08 | (–) | 0.00 | (+) | 37.86 |
| Case 3 February 26 | (+) | 31.85 | (–) | 0.00 | (+) | 33.11 | (–) | 0.00 |
| Case 4 March 8 | (+) | 20.22 | (–) | 0.00 | (+) | 21.25 | (–) | 0.00 |

The RdRP gene was included in this assay to confirm the presence of SARS-CoV-2. Endogenous internal controls of all samples were positive. (+) and (–) represent positive and negative, respectively. Abbreviations: del, deletion; Ct, cycle threshold.

![Fig. 1. Genome sequences of the variants detected in this study.](image-url)
4. Discussion

Many countries are now facing an unexpected rebound of the COVID-19 pandemic, mainly attributable to the emergence of several SARS-CoV-2 variants. Therefore, prompt identification of the variants is critical for controlling disease spread. Although genome sequencing is considered the gold standard for identifying SARS-CoV-2 variants, it has several limitations in terms of swiftness and convenience. In Japan, as of April 23, 2021, randomly selected COVID-19-positive samples were tested for the N501Y mutation at local public health institutes and affiliated hospitals, and the positive samples along with a few negative ones were sent to a central public health institute (National Institute of Infectious Diseases, Tokyo, Japan) for whole-genome sequencing [9]. Although dependent upon several factors, such as the local situation of the COVID-19 epidemic and geographical conditions, it usually takes a week to receive the final report of genome sequencing. This limitation can be overcome by the Novaplex™ SARS-CoV-2 Variants I Assay kit that can substantially shorten the turnaround time.

Since many variants are emerging, there is a possibility that monoplex-based testing can miss detecting some of the characteristic mutations in the variants. We detected two samples with the E484K mutation and without the N501Y mutation in this study. This variant has been named R.1 and categorized as a VOI in Japan as of April 7, 2021; however, this variant could bypass the screening stage in our country. Therefore, we need a multiplex-based test that can examine several mutations simultaneously.

In conclusion, the Novaplex™ SARS-CoV-2 Variants I Assay kit that can substantially shorten the turnaround time.

Acknowledgement

We would like to thank Editage (www.editage.com) for English language editing.

We also thank Dr. Kentaro Tanaka for his technical support in performing genome analysis.

References

[1] World Health Organization, COVID-19 weekly epidemiological update. Special edition: proposed working definitions of SARS-CoV-2 variants of interest and variants of concern, 2021. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20210225_weekly_epi_update_voc-special-edition.pdf?sfvrsn=1eacfa47_7&download=true.

[2] World Health Organization, Weekly epidemiological update on COVID-19, 2021. https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---13-april-2021.

[3] C.E. Gomez, B. Perdiguero, M. Esteban, Emerging SARS-CoV-2 variants and impact in global vaccination programs against SARS-CoV-2/COVID-19, Vaccines 9 (2021) 243, https://doi.org/10.3390/vaccines9030243.

[4] G. Nelson, O. Buzko, P. Spilman, K. Niazi, S. Rabizadeh, P. Soon-Shiong, Molecular dynamics simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K K417n and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant, bioRxiv 2021. doi: 10.1101/2021.01.13.426558.

[5] European Centre for Disease Prevention and Control, and World Health Organization Regional Office for Europe, Methods for the detection and identification of SARS-CoV-2 variants, 2021. https://www.ecdc.europa.eu/sites/default/files/documents/Methods-for-the-detection-and-identification-of-SARS-CoV-2-variants-WHO-ECDC.pdf.

[6] World Health Organization, Genomic sequencing of SARS-CoV-2: a guide to implementation for maximum impact on public health, 2021. https://apps.who.int/iris/handle/10665/358480.

[7] K. Shirato, N. Nao, H. Katano, I. Takayama, S. Saito, F. Kato, et al., Development of generic diagnostic methods for detection for novel coronavirus 2019 (nCoV-2019) in Japan, Jpn. J. Infect. Dis. 73 (4) (2020) 304–307, https://doi.org/10.7883/yoken.JJD.2020.061.

[8] K. Ikawa, T. Sekizuka, M. Hashino, R. Tanaka, M. Kuroda, Disentangling primer interactions improves SARS-CoV-2 genome sequencing by multiplex tiling PCR, PLoS ONE 15 (9) (2020), e0239403, https://doi.org/10.1371/journal.pone.0239403.

[9] T. Takenouchi, Y.W. Iwasaki, S. Harada, H. Ishizu, Y. Uwamino, S. Uno, et al., Clinical utility of SARS-CoV-2 whole genome sequencing in deciphering source of infection, J. Hosp. Infect. 107 (2021) 40–44, https://doi.org/10.1016/j.jhin.2020.10.014.